Search clinical trials for: Latanoprost ophthalmic solution

Total 19509 results

Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

Primary Open Angle Glaucoma or Ocular Hypertension

Japan
Uzoma Chinyei Joan

Recruiting

Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.

Effect of Drug

Nigeria
TearClear Corp

Active, not recruiting

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure (TC-002-301)

Elevated Intraocular Pressure

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma, Ocular Hypertension

Japan
Santen Pharmaceutical Co., Ltd.

Completed

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Peregrine Ophthalmic

Completed

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

Glaucoma

United States
JeniVision, Inc.

Suspended

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open Angle Glaucoma

United States
Santen Pharmaceutical Co., Ltd.

Completed

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Open Angle Glaucoma or Ocular Hypertension

Singapore
Aerie Pharmaceuticals

Completed

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Glaucoma

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
EyePoint Pharmaceuticals, Inc.

Completed

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Kasr El Aini Hospital

Completed

Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

Primary Open Angle Glaucoma

Egypt
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Santen Inc.

Completed

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SEE-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Alcon Research

Completed

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
University of the Incarnate Word

Unknown

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

Glaucoma, Open-Angle

United States
Ophthalmic Consultants of Long Island
Pfizer

Completed

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

Dry Eye Disease

United States
Shaare Zedek Medical Center

Unknown

Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug -EXP-LP (EXP-LP)

Ocular Hypertension | Glaucoma | IOP

Israel
Aerie Pharmaceuticals

Completed

Rocklatan® Evaluation

Glaucoma

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (XLT)

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Alcon Research

Completed

Effects of Travatan Z and Xalatan on Ocular Surface Health

Ocular Hypertension | Glaucoma
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

Ocular Hypertension | Glaucoma

United States, Spain, Italy, Denmark, Portugal, South Africa
Laboratorios Poen

Completed

Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost

Primary Open-angle Glaucoma

Argentina
Mati Therapeutics Inc.

Withdrawn

A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Glaucoma
Mati Therapeutics Inc.

Completed

A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Ocular Hypertension | Open Angle Glaucoma

Canada
Pfizer

Completed

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

Ocular Hypertension | Glaucoma, Open-Angle

United States
University of California, San Francisco

Completed

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Alopecia Areata

United States
Mati Therapeutics Inc.

Completed

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension (CORE)

Ocular Hypertension | Glaucoma

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension

Primary Open Angle Glaucoma | Ocular Hypertension

United Kingdom, France, Australia, Thailand, Portugal, Pakistan, Czechia, Greece
Mati Therapeutics Inc.

Completed

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Glaucoma | Ocular Hypertension (OH)

United States
Mati Therapeutics Inc.

Completed

A Safety Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Yale University
Pfizer

Completed

Effect of Age on Latanoprost 0.005% in Patients With Glaucoma

Glaucoma

United States
Massachusetts Eye and Ear Infirmary
Harvard University

Recruiting

Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Sylentis, S.A.

Completed

HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)

Dry Eye Disease

Spain, Portugal, Italy, Estonia, Germany, Slovakia
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
CHA University
Samil Pharmaceutical Co., Ltd.

Completed

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

Ocular Hypertension | Glaucoma

Korea, Republic of
Pfizer

Completed

Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

Ocular Hypertension | Glaucoma, Open-Angle

Sweden, Finland
Alcon Research

Completed

A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin

Glaucoma

United States
Dr. David Yan
Allergan

Unknown

A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma

Primary Open Angle Glaucoma | Ocular Hypertension | POAG

Canada
Alcon Research

Completed

Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma
Rigshospitalet, Denmark
Laboratoires Thea

Recruiting

Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet Cells

Ocular Hypertension | Glaucoma

Denmark
Nicox Ophthalmics, Inc.

Completed

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Glaucoma, Open-Angle | Hypertension, Ocular

United States
Pharmaceutical Research Network

Completed

Latanoprost Versus Fotil

Ocular Hypertension | Open-Angle Glaucoma

Poland
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States

3

Subscribe